Zanzalintinib

Zanzalintinib (XL092) is a small-molecule drug developed by Exelixis and Merck Sharp & Dohme. Its targets are VEGF / VEGFR and MET (the sponsor names MET/VEGFR/AXL/MER). The sponsor states: Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours), NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma) and NCT07227402 (A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)), in neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma. The largest, NCT07227402, plans to enrol 904 participants with primary completion expected 2032-02-27. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.